Media ReleasesNyrada

View All Nyrada News

Milestone Achieved in the Nyrada Brain Injury Program

Nyrada Inc (ASX: NYR) provides an update on one of its leading programs for treatment of brain injury.

Nyrada has shown in a preclinical pharmacokinetic study that its lead candidate compounds can cross the blood-brain-barrier (BBB) in the intact uninjured animal brain.

The aim of the Nyrada Brain Injury program is a drug to reduce secondary brain damage following head trauma and stroke in order to improve survivability and patient outcomes. 

For more information, download the attached PDF.

Download this document

Are you a 708 sophisticated investor?

If you are a sophisticated investor as defined under Section 708 of the Corporations Act (net assets of $2.5 million or annual incomes in excess of $250,000).

We can alert you to wholesale investment opportunities not available to regular investors.

Please subscribe if you would like to be alerted to these types of opportunities.